ES2133130B1 - Nueva formulacion de budesonida, su uso y recipiente que la contiene. - Google Patents

Nueva formulacion de budesonida, su uso y recipiente que la contiene.

Info

Publication number
ES2133130B1
ES2133130B1 ES009702483A ES9702483A ES2133130B1 ES 2133130 B1 ES2133130 B1 ES 2133130B1 ES 009702483 A ES009702483 A ES 009702483A ES 9702483 A ES9702483 A ES 9702483A ES 2133130 B1 ES2133130 B1 ES 2133130B1
Authority
ES
Spain
Prior art keywords
budesonide
container containing
new formulation
formulation
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009702483A
Other languages
English (en)
Other versions
ES2133130A1 (es
Inventor
Hans Nilsson
Gordon Satensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2133130(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9604486A external-priority patent/SE9604486D0/xx
Application filed by Astra AB filed Critical Astra AB
Publication of ES2133130A1 publication Critical patent/ES2133130A1/es
Application granted granted Critical
Publication of ES2133130B1 publication Critical patent/ES2133130B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

Nueva formulación de budesonida, su uso y recipiente que la contiene. Se describe una nueva dosis unitaria medida que comprende 40 {u g o menos de budesonida así como una formulación de la misma y su uso para el tratamiento de afecciones de la nariz.
ES009702483A 1996-12-05 1997-11-27 Nueva formulacion de budesonida, su uso y recipiente que la contiene. Expired - Fee Related ES2133130B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604486A SE9604486D0 (sv) 1996-12-05 1996-12-05 Novel formulation
US08/846,960 US6291445B1 (en) 1996-12-05 1997-04-29 Low dose budesonide formulations and uses thereof

Publications (2)

Publication Number Publication Date
ES2133130A1 ES2133130A1 (es) 1999-08-16
ES2133130B1 true ES2133130B1 (es) 2000-03-01

Family

ID=26662810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009702483A Expired - Fee Related ES2133130B1 (es) 1996-12-05 1997-11-27 Nueva formulacion de budesonida, su uso y recipiente que la contiene.

Country Status (23)

Country Link
US (2) US6686346B2 (es)
EP (1) EP0907365B1 (es)
JP (1) JP2000508675A (es)
CN (1) CN1168450C (es)
AT (2) ATE239482T1 (es)
AU (1) AU726515B2 (es)
BE (1) BE1011394A5 (es)
CZ (1) CZ295792B6 (es)
DE (2) DE69721766T2 (es)
DK (1) DK0907365T3 (es)
ES (1) ES2133130B1 (es)
FR (1) FR2756739B1 (es)
GR (1) GR1003011B (es)
HK (1) HK1020522A1 (es)
HU (1) HUP0000575A3 (es)
IE (1) IE970854A1 (es)
IL (1) IL125534A (es)
NL (1) NL1007706C2 (es)
NO (1) NO983555D0 (es)
NZ (1) NZ330925A (es)
PT (1) PT907365E (es)
TR (1) TR199801501T1 (es)
WO (1) WO1998024450A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK2214679T3 (da) 2007-11-13 2019-05-20 Meritage Pharma Inc Kortikosteroidsammensætninger
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2303254B1 (en) 2008-06-12 2019-10-30 Medtronic Xomed, Inc. Product for treating chronic wounds with an extracellular polymeric substance solvating system
US20100086576A1 (en) 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
CN112516087B (zh) * 2020-12-24 2023-03-24 四川普锐特药业有限公司 布地奈德鼻喷剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
PL164294B1 (pl) * 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
HU227519B1 (en) * 1991-12-18 2011-07-28 Astra Ab Synergic pharmaceutical composition containing combination of formoterol and budesonide
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
US5509404A (en) 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
AU6290396A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
BR9709650A (pt) * 1996-06-04 1999-08-10 Procter & Gamble Aerosol nasal contendo um esteróide intransal e um anti-histamínico
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide

Also Published As

Publication number Publication date
DE69721766D1 (de) 2003-06-12
HUP0000575A2 (hu) 2000-10-28
WO1998024450A1 (en) 1998-06-11
CZ295792B6 (cs) 2005-11-16
IL125534A (en) 2003-06-24
GR970100477A (el) 1998-08-31
NL1007706C2 (nl) 1998-09-22
EP0907365A1 (en) 1999-04-14
US20020016315A1 (en) 2002-02-07
BE1011394A5 (fr) 1999-08-03
JP2000508675A (ja) 2000-07-11
PT907365E (pt) 2003-09-30
TR199801501T1 (xx) 1999-02-22
GR1003011B (el) 1998-11-20
CN1210467A (zh) 1999-03-10
US20040101486A1 (en) 2004-05-27
AU5421198A (en) 1998-06-29
NZ330925A (en) 2000-05-26
DE69721766T2 (de) 2004-03-04
DE69738000D1 (de) 2007-09-20
NO983555L (no) 1998-08-03
ATE239482T1 (de) 2003-05-15
IE970854A1 (en) 1998-10-07
EP0907365B1 (en) 2003-05-07
CZ243798A3 (cs) 1998-11-11
FR2756739A1 (fr) 1998-06-12
HK1020522A1 (en) 2000-05-12
HUP0000575A3 (en) 2001-03-28
FR2756739B1 (fr) 2000-04-28
ATE369118T1 (de) 2007-08-15
CN1168450C (zh) 2004-09-29
ES2133130A1 (es) 1999-08-16
NL1007706A1 (nl) 1998-06-08
IL125534A0 (en) 1999-04-11
NO983555D0 (no) 1998-08-03
DE69738000T2 (de) 2008-04-17
AU726515B2 (en) 2000-11-09
DK0907365T3 (da) 2003-08-04
US6686346B2 (en) 2004-02-03
US6986904B2 (en) 2006-01-17

Similar Documents

Publication Publication Date Title
ES2133130B1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
AR019503A1 (es) Utilizacion de derivados sustituidos en 3 del estilbeno como agentes activos desodorantes en las composiciones cosmeticas
SE9704186D0 (sv) New composition of matter
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
SE9604486D0 (sv) Novel formulation
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
FI935464A (fi) Klorfluorkolfria aerosolformulationer
ATE208621T1 (de) Stabilisierung der prostaglandinzusammensetzungen
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
AR021391A1 (es) Inhaladores presurizados de dosis medidas (mdi) y su uso.
AR009849A1 (es) Compuestos estilbenicos de grupo adamantil, composiciones que los contienen y utilizaciones
ES2092860T3 (es) Composiciones de silicona para el cuidado de la piel.
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
AR008908A1 (es) Uso de loratadina y un descongestivo para preparar un medicamento para mejorar la funcion pulmonar de un paciente que padece asma
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ES2172589T3 (es) Tratamiento de la apoplegia asociada con la infiltracion de macrofagos.
ES2065307T3 (es) Producto y procedimiento para el moldeado permanente del cabello.
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2103220B1 (es) Desodorantes de los efluentes de papelera a base de ester de acido undecilenico.
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
NO963208D0 (no) Anvendelse av 1,3,2-benzoditiazol-1-oksyder som mikrobiocider for beskyttelse av tekniske materialer såvel som visse 1,3,2-benzoditiazol-1-oksyder
ES2196306T3 (es) Mezclas solidas de sales de 2,2-dioxido de 3-isorpopil-2.1.3-benzotiadiazin-4-ona.
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene
ECSP972300A (es) Tratamiento del asma

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990816

Kind code of ref document: A1

Effective date: 19990816

FD2A Announcement of lapse in spain

Effective date: 20180807